Use these links to rapidly review the document TABLE OF CONTENTS PART IV Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exac ...

Catabasis Pharmaceuticals Inc. (CATB) Q3 2019 Earnings Conference Call November 7, 2019 8:30 AM ET Company Participants Andrea Matthews – Vice President-Corporate Affairs Jill Milne – Chief Executive Officer Joanne Donovan – Chief Medical Officer Andrew Komjathy – Chief Commercial Officer Andy Nichols – Chief Scientific Officer Noah Clauser – Vice President-Finance Conference Call Participants Joel Beatty – Citi Jackie Yan – Oppenheimer and Company. Operator Ladies and gentlemen, thank you for standing-by a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ...

Catabasis Pharmaceuticals Inc. (CATB) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Jill Milne - Chief Executive Officer Noah Clauser - Vice President, Finance Joanne Donovan - Senior Vice President, Clinical Development, Chief Medical Officer Andrew Nichols - Chief Scientific Officer Andrea Matthews - Vice President, Corporate Affairs Conference Call Participants Hartaj Singh - Oppenheimer Joel Beatty - Citi Operator Good day ladies and gentlemen and welcome to the Q2 201 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-3687168 ...

Catabasis Pharmaceuticals, Inc. (CATB) Q1 2019 Earnings Conference Call May 14, 2019 8:30 AM ET Company Participants Andrea Matthews - Vice President-Corporate Affairs Jill Milne - Chief Executive Officer Joanne Donovan - Chief Medical Officer Andrew Nichols - Chief Scientific Officer Noah Clauser - Vice President of Finance Conference Call Participants Liana Moussatos - Wedbush Securities, Inc. Joel Beatty - Citigroup Hartaj Singh - Oppenheimer & Co., Inc. Operator Good day, ladies and gentlemen, and welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37467 Catabasis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-368716 ...